You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies

    SBC: Alterna Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Automated CRISPR Screening Using the CellRaft Technology

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY GlioblastomaGBMis an intractable cancer with an average survival time oftomonthsTreatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrierbut engineered neural stem cellsNSCshold great promise as GBM therapies because they selectively migrate to tumor cells and can ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. MegaTrans- human transporter machine learning models

    SBC: COLLABORATIONS PHARMACEUTICALS, INC.            Topic: 400

    Summary Being able to predict interactions with important human transporters would be of value to new drug design to avoid compounds that interact with them and cause undesirable side effectsOATP BSLCO Band OATP BSLCO Bare `uptakeandapostransporters largely restricted to the sinusoidal aspect of hepatocytesThey both transport a wide variety of structurally unrelated compoundsincluding members of s ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Good Bowls: Empowering Communities to Achieve Good Food Access and Health Equity

    SBC: Good Bowls,LLC            Topic: 102

    PROJECT SUMMARY Povertyethnic minority statusand rural residence are strong predictors of poor healthThere are multiple contributors to high chronic disease ratesincluding food insecuritylack of access to affordablenutritionally valuable foodand unemploymentRural poverty in the Southeast is exacerbated by reduced economic opportunity associated with agricultural transitions and historical loan dis ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Overmillion Americans have asthmawhich places an economic burden on the U Sof $billionAirway mucus overproduction is a hallmark of asthmaand the quantity and tenacity of mucus are increased during airway exacerbationsMucolytics degrade mucusbut do not reduce its productionAlthough corticosteroids and other anti inflammatory therapies indirectly decrease mucus productionand anti cho ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Regenerative rotator cuff repair in a clinically relevant chronic disease model

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Rotator cuff repairRCRis a common first line surgical solution to symptomatic rotator cuff injurywith overRCRs performed annuallyand growing at a rate ofUnfortunatelyof the cases are complicated by failure and re tear of the repaired tendonwhich commonly results in a significant reduction in activities of daily livingworkand or sports and recreation for the patient due to pain and restric ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government